Suven Life Sciences vs Sun Pharma Advanced Research: Share Price, PE, ROE Compared

August 12, 2026
Posted by: Kunal Singla
Category: Market

Suven Life Sciences MCap Rs 9,404 Cr, LOSS-MAKING (EPS -12.47, ROE -46.73%). Sun Pharma Advanced Research (SPARC) MCap approx Rs 1,000-2,000 Cr (data approximate).

Suven Life Sciences vs Sun Pharma Advanced Research (SPARC) is a comparison pharma research investors look up when evaluating two listed Indian companies focused on drug discovery and pharmaceutical R&D. Suven Life Sciences, a Hyderabad-based company, is a CNS (central nervous system) drug discovery and development company – it separated from Suven Pharmaceuticals and focuses exclusively on developing proprietary CNS drug candidates for psychiatric and neurological disorders. Sun Pharma Advanced Research Company (SPARC), a Mumbai-based company (Sun Pharmaceutical subsidiary), is a specialty pharma R&D company pursuing novel drug delivery and NCE (new chemical entity) drug development. Both Suven Life Sciences and SPARC are R&D-stage companies with significant research pipelines – Suven is currently loss-making.

This Suven Life Sciences vs Sun Pharma Advanced Research article covers reach and market position, key products, latest declared results and stock valuation. All data is sourced from Groww and public company filings.

Table of Contents

Reach and Market Position

In this Suven Life Sciences vs Sun Pharma Advanced Research comparison, Suven Life Sciences develops CNS drug candidates (GABA-A modulators, neurotensin receptor agonists) through clinical trials for licensing to global pharma partners. Market capitalisation is Rs 9,404 Cr.

Click Here – Get Free Investment Predictions

Sun Pharma Advanced Research develops novel drug delivery systems (NDDS), NCEs and specialty pharma products for Sun Pharma commercialisation. Market capitalisation is approximately Rs 1,000-2,000 Cr.

Key Products and Business Mix

For the Suven Life Sciences vs Sun Pharma Advanced Research product breakdown, Suven Life Sciences: Suven earns from milestone payments and licensing of CNS drug candidates. EPS is -Rs 12.47 (LOSS-MAKING!). ROE is -46.73 percent. Suven Life Sciences is loss-making – typical for an early-stage drug discovery company with high R&D spend.

Sun Pharma Advanced Research: SPARC earns from milestone payments and drug development fees from Sun Pharma. Data is approximate – verify current financials from exchange filings.

Latest Results and Financial Data

On the Suven Life Sciences vs Sun Pharma Advanced Research results front: Suven Life Sciences has a market cap of Rs 9,404 Cr and is LOSS-MAKING with EPS -12.47 and ROE -46.73 percent. The loss reflects heavy R&D investment in CNS pipeline.

SPARC has a market cap of approximately Rs 1,000-2,000 Cr. As a Sun Pharmaceutical subsidiary, SPARC has parent company backing. Verify current financials from exchange filings.

Compare Suven Life Sciences and Sun Pharma Advanced Research Fundamentals on the Univest Screener

Stock Performance and Valuation

Investors tracking the Suven Life Sciences vs Sun Pharma Advanced Research comparison should verify current prices on NSE or BSE before trading. The Suven Life Sciences vs Sun Pharma Advanced Research stock data below reflects the latest available figures from Groww and public company filings.

Suven Life Sciences versus SPARC: Suven (Rs 9,404 Cr, LOSS-MAKING, CNS R&D) vs SPARC (approx Rs 1,000-2,000 Cr, NDDS/NCE, Sun Pharma subsidiary). Both are R&D-stage pharma companies – high-risk, high-potential investments.

Suven Life Sciences vs Sun Pharma Advanced Research: Quick Comparison Table

The comparison table below summarises the key metrics side by side.

Parameter	Suven Life Sciences	Sun Pharma Advanced Research
Sector	CNS drug discovery: Alzheimer’s, schizophrenia pipeline (Hyderabad, stand-alone R&D)	NDDS + NCE drug development (Sun Pharma subsidiary, Mumbai)
Market Cap	Rs 9,404 Cr	Approx Rs 1,000-2,000 Cr
Profitability	LOSS-MAKING (EPS -12.47, ROE -46.73%)	Approx (verify from filings)
R&D Focus	CNS: GABA-A, psychiatric + neurological drugs	Novel drug delivery + new chemical entities
Parent	Independent (demerged from Suven Pharmaceuticals)	Sun Pharmaceutical Industries
Revenue	Milestone + licensing income (no product revenue yet)	Development fees + milestones from Sun Pharma
Risk Profile	Very high (early-stage CNS pipeline)	High (R&D stage, Sun Pharma backing helps)

Conclusion

The Suven Life Sciences vs Sun Pharma Advanced Research comparison above covers reach, products, results and valuation. Suven Life Sciences versus Sun Pharma Advanced Research covers two India-based pharma R&D companies at different stages of the drug development pipeline. Suven is an independent CNS drug discoverer with a deep pipeline but is loss-making. SPARC benefits from Sun Pharma’s resources. Both are high-risk R&D plays. The Suven and SPARC comparison shows two fundamentally different business risk profiles from traditional pharma companies. Consult a SEBI-registered advisor before investing in early-stage pharma R&D companies.

Download the Univest iOS App or Univest Android App to track Suven Life Sciences and Sun Pharma Advanced Research live price and get daily stock recommendations.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

Frequently Asked Questions

What does Suven Life Sciences do?

Ans. Suven Life Sciences discovers and develops CNS (central nervous system) drugs – primarily targeting Alzheimer’s disease, schizophrenia, major depressive disorder and other neurological conditions. It licenses compounds to global pharma companies.

What does Sun Pharma Advanced Research do?

Ans. SPARC (Sun Pharma Advanced Research Company) develops novel drug delivery systems (NDDS – controlled release, transdermal patches, nano particles) and new chemical entities for Sun Pharma’s pipeline.

Is Suven Life Sciences profitable?

Ans. No. Suven Life Sciences is currently loss-making with EPS -12.47 and ROE -46.73 percent – typical for a drug discovery company spending heavily on clinical trials.

What is CNS drug discovery?

Ans. CNS (Central Nervous System) drug discovery involves finding and developing molecules that treat brain disorders – Alzheimer’s, Parkinson’s, schizophrenia, epilepsy. CNS R&D is notoriously long-duration (10-20 years) and capital-intensive.

Which is larger, Suven or SPARC?

Ans. Suven Life Sciences at Rs 9,404 Cr is approximately 5-9 times larger than SPARC at approximately Rs 1,000-2,000 Cr.

Is SPARC part of Sun Pharma?

Ans. Yes. Sun Pharma Advanced Research Company (SPARC) is a subsidiary of Sun Pharmaceutical Industries – India’s largest pharmaceutical company.

Are Suven and SPARC in Nifty 50?

Ans. Neither is in Nifty 50.

News

Author: Kunal Singla

Kunal Singla is the Associate Director - Research at Univest, leading quantitative equity research, intraday trading setups, and derivatives strategy. With 4+ years of experience in Indian equity markets, he combines rigorous quantitative methods with classical technical analysis to build high-conviction research frameworks for retail and advisory clients. He holds an MSc from the Indian Institute of Technology (IIT) Delhi — one of India's most selective institutions — and has completed the Certificate in Quantitative Finance (CQF), a globally recognised programme covering derivatives pricing, risk modelling, machine learning for finance, and advanced portfolio theory. This combination places him in a small group of Indian analysts with both deep academic training in quantitative methods and SEBI-recognised research credentials. Kunal holds seven SEBI-recognised NISM certifications spanning research, derivatives, portfolio management, and securities operations: Series-XV (Research Analyst), Series-XXI-A (Portfolio Managers), Series-XVI (Commodity Derivatives), Series-VIII (Equity Derivatives), Series-VII (SORM), Series-V-A (Mutual Fund Distributors), and Series-I (Currency Derivatives). At Univest — India's SEBI-registered research and advisory platform — Kunal leads research inputs for Pro Lite, Pro Super, Pro Gold, and Pro Commodity advisory services, alongside publishing intraday stock picks on Univest Blogs.